Targeting the mTOR pathway in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The mechanistic target of rapamycin (mTOR) pathway regulates cell growth, metabolism, and aging.
• mTOR is frequently upregulated in various cancers, including breast cancer.
• Aberrant mTOR signaling is a key driver of breast tumor progression.

Purpose of the Study:

• To review the fundamental role of the mTOR pathway in breast tumors.
• To identify key molecules involved in aberrant mTOR activation in breast cancer.
• To summarize current therapeutic strategies targeting the mTOR pathway for breast cancer treatment.

Main Methods:

• Literature review of preclinical models and clinical trials.
• Analysis of molecular mechanisms underlying mTOR pathway activation in breast cancer.
• Evaluation of therapeutic agents targeting mTOR components.

Main Results:

• mTOR pathway inhibition with rapamycin and rapalogs demonstrates potent reduction of breast cancer tumor growth.
• Preclinical and clinical data support the efficacy of mTOR inhibitors.
• Key molecules driving aberrant mTOR activation have been identified.

Conclusions:

• The mTOR pathway is a critical regulator of breast cancer.
• Targeting mTOR with inhibitors offers a promising therapeutic strategy for breast cancer.
• Development of predictive biomarkers is essential for patient stratification and optimizing mTOR-targeted therapies.